Alliances Update
Tags: STRATEGIC alliances (Business); PHARMACEUTICAL industry; AGENSYS Inc.; CYTOKINETICS Inc.; SIRNA Therapeutics Inc.; PARTNERSHIP (Business)
Related Articles
- Merck & Co.: Sirna takeover heralds end of alliance. // PharmaWatch: Monthly Review;Nov2007, Vol. 6 Issue 11, p36
The article reports on the end of Alnylam Pharmaceuticals Inc. and Merck & Co. Inc.'s research partnership in the U.S. According to the article, the reason for the separation is the latter's move to complete a $1.1 billion takeover by Sirna Therapeutics Inc. In addition, Alnylam has decided to...
- Becoming the Partner of Choice. Slowinski, Gene // Pharmaceutical Executive;Dec2001, Vol. 21 Issue 12, p52
Discusses findings of a study on co-promotion agreements and strategic alliances in the pharmaceutical industry in the United States. Reason for entering into co-promotion alliances; Characteristics sought from a strategic partner; Reasons for the failure of partnerships; Basis for selecting a...
- Alliances Update. // PharmaWatch: Biotechnology;May2006, Vol. 5 Issue 5, p18
The article offers news briefs related to the pharmaceutical industry worldwide in 2006. SGX Pharmaceuticals Inc. has closed a deal with the Novartis AG for the development of leukemia therapies. Sirna Therapeutics Inc. has partnered with GlaxoSmithKline PLC to develop therapies for respiratory...
- Strategic alliances and competitive performance in the pharmaceutical industry. Gon�alves, Francisco Rocha; Gon�alves, V�tor da Concei��o // Journal of Medical Marketing;Jan2008, Vol. 8 Issue 1, p69
This paper aims to improve knowledge about the relationship between strategic alliances and performance. It begins by proposing a moderating role for the alliance management capability. Next, it advances an explanation of the impact of the alliances on performance, which is based on the firms�...
- Growing Pains: As Biotechs Mature, Pacts Become More Complex. Jarvis, Lisa // Chemical Market Reporter;2/25/2002, Vol. 261 Issue 8, p10
Reports on the partnership between emerging biotechnology industry and pharmaceuticals industry. Issues on partnership and strategic alliances discussed at the conference of the Biotechnology Industry Organization; Important factors to consider to have a successful partnership; Method of...
- Enlightenment from the Big Pharmas. // Bioworld Week;7/14/2008, Vol. 16 Issue 28, p4
The article reports on the collaboration of three pharmaceutical firms to create the Boston, Massachusetts-based Enlight Biosciences which focuses on developing pre-competitive technologies. It is noted that Enlight Biosciences is a collaboration among PureTech Ventures, Eli Lilly & Co., Merck &...
- Becoming a premier partner: Measuring, managing and changing partnering capabilities at Eli Lilly and Company. Futrell, David; Slugay, Marlene; Stephens, Carol H. // Journal of Commercial Biotechnology;Summer2001, Vol. 8 Issue 1, p5
When Eli Lilly and Company decided to expand its drug development by entering into strategic 'alliances' with other, usually smaller, biotechnology firms, the company committed to becoming the 'premier partner' in the pharmaceutical industry. To implement that commitment, Lilly needed a way to...
- Pharma-Biotech Partnerships. Malik, Nafees N. // Pharmaceutical Technology;Aug2009, Vol. 33 Issue 8, p113
The article discusses the impact of the partnership between pharmaceutical and biotechnology on most pharmaceutical companies in the U.S. The author suggests that traditional companies are good at developing large numbers of high-earning small-molecule drugs. A study suggests that in 2007...
- Japanese Pharmaceutical Companies Seek Partners. // BioPharm International;Mar2004, Vol. 17 Issue 3, p14
Reports on the interest of Japanese pharmaceutical firms to partner up with American companies. Expected decline of the Japanese pharmaceutical market; Market expansion pressure faced by the Japanese pharma companies; Assertion of Tokyo-based mergers and acquisitions attorney Scott T. Jones,...
